摘要
目的研究本地区大肠埃希菌产超广谱β-内酰胺酶与AmpC酶耐药性。方法收集临床分离无重复大肠埃希菌共116株,利用双纸片协同法检测超广谱β-内酰胺酶(ESBLs);利用3-氨基苯酚硼酸对AmpCβ-内酰胺酶的抑制作用检测表型AmpC酶。K-B法测定细菌对抗生素的耐药性。结果116株大肠埃希菌ESBLs阳性43株(37.1%),ESBLs与AmpC酶同时阳性10株(8.6%),表型未检出AmpC酶单独阳性株。大肠埃希菌的产酶株及非产酶株对碳青霉烯类100%敏感,但产酶株(尤其是同时产ESBLs与AmpC酶)比非产酶株耐药率高,多重耐药性更常见。结论从本院患者送检标本分离的大肠埃希菌中发现AmpC酶,应引起临床重视。碳青霉烯类药物可作为治疗产酶细菌感染的首选药物。
Objective To study the antibiotic resistance phenotypes of extended spectrum β-lactamases（ESBLs） and AmpC β-lactamase-producing escherichia coli isolated from the patients in our district. Methods A total of 116 clinical isolates of nonrepeated escherichia coli were collected from the patients . Double disk synergy test was used to detect ESBLs. AmpC beta-lactamase was detected based on the rule that AmpC beta lactamase can be inhibited by 3-aminophenylboronic acid（APB）. Kirby-bauer agar diffusion method was used to judge the drug sensitivity. Results ESBLs were positive in 43 out of 116 isolates（ 37. 1%） ,Both ESBI.s and AmpC β- lactamases were positive in 10 out of 116 isolates（ 8.6%）, AmpC β-lactamase single producer was not detected out in terms of phenotype. Although all strains were susceptible to carbpenem,esherichla coli with β-lactamases were more resistant to other antibiotic agents than those without β-lactamases. Conclusion AmpC beta- lactamase mediated by plasmid could be de teeted in E. eoli isolates from the patients in our district. So a great attention should be paid in the clinic. And carbapenems could function as the first choice for the treatment of infection caused by AmpC β-lactamase producers.
出处
《检验医学与临床》
CAS
2010年第8期714-715,共2页
Laboratory Medicine and Clinic
